Rischio di iperomocisteinemia in pazienti con epilessia, portatori del diplotipo C677T/A1298C della MTHFR

Translated title of the contribution: The risk of hyperhomocysteinemia in patients with epilepsy exhibiting the diplotype C677T/A1298C of MTHFR

G. Gorgone*, D. Caccamo, S. Condello, V. Belcastro, D. Italiano, L. R. Pisani, G. Badolato, P. Striano, G. Oteri, R. Ientile, F. Pisani

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

This study was aimed at investigating the impact of antiepileptic drugs (AEDs) on hyperhomocysteinemia (hyper-Hcy) in 71 epileptic patients (pts) (40 M, 31 F; 19-41 aa) exhibiting the CT677/AC1298 diplotype of MTHFR gene. 26 pt (36.6%) showed hyper-Hcy (> 13 μmol/); of them, 20 were treated with enzyme-inducing AEDs and 6 with enzyme-inducing AEDs added on to non enzyme inducing drugs. Pts exclusively treated with enzyme-inducing AEDs exhibited lower serum folate concentrations (3.28 ± 1.82 nmol/L p < 0.01) and higher plasma Hey levels (18.32 ± 5.52 μmol/L p < 0.001) as compared to other groups. These pts showed a positive risk association for hyper-Hcy (OR = 3.8, CI = 1.04-14.4). Folate supplementation (5 mg/day) restored both Hcy and folate levels within the normal ranges.

Translated title of the contributionThe risk of hyperhomocysteinemia in patients with epilepsy exhibiting the diplotype C677T/A1298C of MTHFR
Original languageItalian
Pages (from-to)21-23
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number129-130
StatePublished - 2005

Keywords

  • Antiepileptic drugs
  • Epilepsy
  • Folate
  • Hyperhomocysteinemia
  • MTHFR

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'The risk of hyperhomocysteinemia in patients with epilepsy exhibiting the diplotype C677T/A1298C of MTHFR'. Together they form a unique fingerprint.

Cite this